ANDA 75627, held by Teva Parenteral. Acyclovir Sodium.
As of Nov 14, 2026, ANDA 75627 (Acyclovir Sodium), held by Teva Parenteral, was first approved by FDA on Mar 28, 2001, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 28, 2001 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Acyclovir SodiumEQ 50MG BASE/ML ยท injectable;injection | Acyclovir Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
